Triple therapy in refractory detrusor overactivity: A preliminary study

World Journal of Urology

Volumn 28, Issue 1, 2010, Pages 79-85

  Natalin, Ricardo ^a   Reis, Leonardo Oliveira ^a,b   Alpendre, Cristiano ^a   Ikari, Lia Y ^a   Prudente, Alessandro ^a   D'Ancona, Carlos A L ^a  

^a UNIVERSITY OF CAMPINAS   (Brazil)

^b NONE   (Brazil)

Author keywords

Clinical treatment; Detrusor overactivity; Off label; Refractory; Triple therapy; Urodynamic evaluation

Indexed keywords

ALPHA ADRENERGIC RECEPTOR BLOCKING AGENT; DOXAZOSIN; IMIPRAMINE; MANDELIC ACID DERIVATIVE; MUSCARINIC RECEPTOR BLOCKING AGENT; OXYBUTYNIN; TRICYCLIC ANTIDEPRESSANT AGENT;

ADOLESCENT; ADULT; AGED; ARTICLE; CHILD; DRUG COMBINATION; DRUG POTENTIATION; FEMALE; HUMAN; MALE; MIDDLE AGED; OVERACTIVE BLADDER; PROSPECTIVE STUDY;

ADOLESCENT; ADRENERGIC ALPHA-ANTAGONISTS; ADULT; AGED; ANTIDEPRESSIVE AGENTS, TRICYCLIC; CHILD; DOXAZOSIN; DRUG SYNERGISM; DRUG THERAPY, COMBINATION; FEMALE; HUMANS; IMIPRAMINE; MALE; MANDELIC ACIDS; MIDDLE AGED; MUSCARINIC ANTAGONISTS; PROSPECTIVE STUDIES; URINARY BLADDER, OVERACTIVE; YOUNG ADULT;

EID: 75849138166     PISSN: 07244983     EISSN: 14338726     Source Type: Journal    
DOI: 10.1007/s00345-009-0400-6     Document Type: Article

References (43)

1. Hashim H, Abrams P (2004) Drug treatment of overactive bladder: efficacy, cost and quality-of-life considerations. Drugs 64: 1643-1656.
2. Abrams P, Andersson KE (2007) Muscarinic receptor antagonists for overactive bladder. BJU Int 100: 987-1006.
3. Abrams P, Cardozo L, Fall M et al (2003) The standardisation of terminology in lower urinary tract function: report from the standardisation sub-committee of the International Continence Society. Urology 61: 37-49.
4. Brown JS, McGhan WF, Chokroverty S (2000) Comorbidities associated with overactive bladder. Am J Manag Care 6: 574-579.
5. Kilic N, Balkan E, Akgoz S et al (2006) Comparison of the effectiveness and side-effects of tolterodine and oxybutynin in children with detrusor instability. Int J Urol 13: 105-108.
6. Wein AJ (1998) Pharmacologic options for the overactive bladder. Urology 51: 43-47.
7. Hawthorn MH, Chapple CR, Cock M et al (2000) Urothelium-derived inhibitory factor(s) influences on detrusor muscle contractility in vitro. Br J Pharmacol 129: 416-419.
8. Kim Y, Yoshimura N, Masuda H, de Miguel F, Chancellor MB (2005) Antimuscarinic agents exhibit local inhibitory effects on muscarinic receptors in bladder afferent pathways. Urology 65: 238-242.
9. Finney SM, Andersson KE, Gillespie JI et al (2006) Antimuscarinic drugs in detrusor overactivity and the overactive bladder syndrome: motor or sensory actions? BJU Int 98: 503-507.
10. Andersson KE, Yoshida M (2003) Antimuscarinics and the overactive detrusor-which is the main mechanism of action? Eur Urol 43: 1-5.
11. Kim Y, Yoshimura N, Masuda H et al (2006) Intravesical installation of human urine after oral administration of trospium, tolterodine and oxybutynin in a rat model of detrusor overactivity. BJU Int 97: 400-403.
12. MacDiarmid SA (2007) Maximizing anticholinergic therapy for overactive bladder: has the ceiling been reached? BJU Int 99: 8-12.
13. Dmochowski R (2002) Interventions for detrusor overactivity: the case for multimodal therapy. Rev Urol 4: 19-27.
14. Ruggieri MR Sr, Braverman AS, Pontari MA (2005) Combined use of alpha-adrenergic and muscarinic antagonists for the treatment of voiding dysfunction. J Urol 174: 1743-1748.
15. Salvatore S, Soligo M, Proietti F et al (2005) Overactive bladder syndrome: considerations in pharmacotherapy and new perspectives. Eur J Obstet Gynecol Reprod Biol 120: 129-133.
16. Chen Q, Takahashi S, Zhong S et al (2005) Function of the lower urinary tract in mice lacking a1d-adrenoceptor. J Urol 174: 370-374.
17. Chapple CR, Roehrborn CG (2006) A shifted paradigm for the further understanding, evaluation, and treatment of lower urinary tract symptoms in men: focus on the bladder. Eur Urol 49: 651-659.
18. Penttila J, Syvalahti E, Hinkka S et al (2001) The effects of amitriptyline, citalopram and reboxetine on autonomic nervous system. A randomised placebo-controlled study on healthy volunteers. Psychopharmacology (Berl) 154: 343-349.
19. Andersson KE (2000) Treatment of overactive bladder: other drug mechanisms. Urology 55: 51-57.
20. Sacco E, Pinto F, Bassi P (2008) Emerging pharmacological targets in overactive bladder therapy: experimental and clinical evidences. Int Urogynecol J 19: 583-598.
21. Miller KL, Dubeau CE, Bergmann M, Griffiths DJ, Resnick NM (2002) Quest for a detrusor overactivity index. J Urol 167: 578-585.
22. Sellers DJ, McKay N (2007) Developments in the pharmacotherapy of the overactive bladder. Curr Opin Urol 17: 223-230.
23. Witte LPW, Mulder WMC, de la Rosette JJMCH, Miche MC (2009) Muscarinic receptor antagonists for overactive bladder treatment: does one fit all? Curr Opin Urol 19: 13-19.
24. Andersson KE (2006) Treatment-resistant detrusor overactivity-underlying pharmacology and potential mechanisms. Int J Clin Pract 60: 8-16.
25. Novara G, Galfano A, Ficarra V et al (2006) Anticholinergic drugs in patients with bladder outlet obstruction and lower urinary tract symptoms: a systematic review. Eur Urol 50: 675-683.
26. Horstmann M, Schaefer T, Aguilar Y et al (2006) Neurogenic bladder treatment by doubling the recommended antimuscarinic dosage. Neurourol Urodyn 25: 441-445.
27. Menarini M, Del Popolo G, Di Benedetto P et al (2006) Trospium chloride in patients with neurogenic detrusor overactivity: is dose titration of benefit to the patients? Int J Clin Pharmacol Ther 44: 623-632.
28. Amend B, Hennenlotter J, Schafer T, Horstmann M, Stenzl A, Sievert K (2008) Effective treatment of neurogenic detrusor dysfunction by combined high-dosed antimuscarinics without increased side-effects. Eur Urol 53: 1021-1028.
29. Payne CK, Kelleher C (2007) Redefining response in overactive bladder syndrome. BJU Int 99: 101-106.
30. Kobelt G, Borgstrom F, Mattiasson A (2003) Productivity, vitality and utility in a group of healthy professionally active individuals with nocturia. BJU Int 91: 190-195.
31. Samuelsson E, Victor A, Tibblin G (1997) A population study of urinary incontinence and nocturia among women aged 20-59 years. Prevalence, well being and wish for treatment. Acta Obstet Gynecol Scand 76: 74-80.
32. Irwin DE, Milsom I, Kopp Z et al (2006) Impact of overactive bladder symptoms on employment, social interactions and emotional well being in six European countries. BJU Int 97: 96-100.
33. Fultz N, Girts T, Kinchen K et al (2005) Prevalence, management and impact of urinary incontinence in the workplace. Occup Med 55: 552-557.
34. Hashim H, Abrams P (2007) Overactive bladder: an update. Curr Opin Urol 17: 231-236.
35. Brown JS, Vittinghoff E, Wyman JF et al (2000) Urinary incontinence: does it increase risk for falls and fractures? Study of Osteoporotic Fractures Research Group. J Am Geriatr Soc 48: 721-725.
36. Milsom I, Abrams P, Cardozo L et al (2001) How widespread are the symptoms of an overactive bladder and how are they managed? A population-based prevalence study. BJU Int 87: 760-766.
37. Reeves P, Irwin D, Kelleher C et al (2006) The current and future burden and cost of overactive bladder in five European countries. Eur Urol 50: 1050-1057.
38. Serels S, Stein M (1998) Prospective study comparing hyoscyamine, doxazosin, and combination therapy for the treatment of urgency and frequency in women. Neurourol Urodyn 17: 31-36.
39. Staskin DR, MacDiarmid SA (2006) Using anticholinergics to treat overactive bladder: the issue of treatment tolerability. Am J Med 119: 9-15.
40. Andersson KE, Chapple CR (2001) Oxibutinin and the overactive bladder. World J Urol 19: 319-323.
41. Serrano Brambila EA, Quiroga Avila RG, Lorenzo Monterrubio JL et al (2000) Assessment of effectiveness of and tolerance to oxybutynin in the treatment of unstable bladder in women. Ginecol Obstet Mex 68: 174-181.
42. Brostrom S, Hallas J (2009) Persistence of antimuscarinic drug use. Eur J Clin Pharmacol. doi: 10. 1007/s00228-008-0600-9.
43. Witte LPW, Mulder WMC, de la Rosette JJMCH, Miche MC (2009) Muscarinic receptor antagonists for overactive bladder treatment: does one fit all? Curr Opin Urol 19: 13-19.